Zentalis Pharmaceuticals (ZNTL) Projected to Announce Earnings on Tuesday

Zentalis Pharmaceuticals (NASDAQ:ZNTL) will likely be posting its Q3 2026 resultson Tuesday, November 10th. Analysts expect Zentalis Pharmaceuticals to post earnings of ($0.58) per share for the quarter. Individuals are encouraged to explore the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Friday, November 13, 2026 at 4:00 PM ET.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.10). On average, analysts expect Zentalis Pharmaceuticals to post ($2.11) EPS for the current fiscal year and ($2.21) EPS for the next fiscal year.

Zentalis Pharmaceuticals Trading Up 1.4%

Shares of NASDAQ:ZNTL traded up $0.03 during trading on Tuesday, reaching $1.88. 365,621 shares of the company traded hands, compared to its average volume of 1,530,732. Zentalis Pharmaceuticals has a 52-week low of $1.21 and a 52-week high of $6.95. The firm has a market capitalization of $134.38 million, a price-to-earnings ratio of -0.96 and a beta of 1.93. The business’s fifty day moving average is $2.91 and its 200-day moving average is $3.44.

Analyst Ratings Changes

A number of research firms recently commented on ZNTL. Jefferies Financial Group upgraded shares of Zentalis Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Wednesday, October 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zentalis Pharmaceuticals in a research note on Friday, October 2nd. William Blair initiated coverage on shares of Zentalis Pharmaceuticals in a report on Wednesday, September 16th. They set an “outperform” rating for the company. Leerink Partners started coverage on shares of Zentalis Pharmaceuticals in a report on Monday, October 5th. They set an “outperform” rating and a $8.00 target price for the company. Finally, Rodman & Renshaw assumed coverage on shares of Zentalis Pharmaceuticals in a report on Thursday, July 23rd. They issued a “buy” rating and a $11.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $7.50.

Insider Activity at Zentalis Pharmaceuticals

In other news, major shareholder Group Walters bought 4,335,000 shares of the stock in a transaction dated Friday, August 14th. The stock was bought at an average price of $3.50 per share, for a total transaction of $15,172,500.00. Following the purchase, the insider directly owned 17,844,973 shares in the company, valued at $62,457,405.50. This trade represents a 32.09% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 3.80% of the stock is currently owned by insiders.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc (NASDAQ:ZNTL) is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule medicines for the treatment of cancer. The company’s research is centered on therapies designed to target biological pathways involved in tumor growth, survival and resistance to existing treatments.

Zentalis’ lead product candidate is azenosertib, formerly known as ZN-c3, an oral inhibitor of WEE1, a protein involved in regulating the cell cycle and DNA-damage response.